Recombinant Cynomolgus IGFBP-3 Protein (HEK293)，His

Insulin-like growth factor binding protein 3 (IGFBP-3) is a key regulator of insulin-like growth factor (IGF) actions, playing a critical role in cellular growth, differentiation, and apoptosis. It binds to IGF with high affinity, modulating its bioavailability and activity in various physiological contexts. Given its significant involvement in cancer biology, particularly in tumor growth and metastasis, IGFBP-3 has garnered attention as a potential therapeutic target. Research has shown that alterations in IGFBP-3 levels are associated with various malignancies, emphasizing its importance in cancer prognosis and treatment. Moreover, recombinant forms of IGFBP-3 are being explored for therapeutic applications due to their ability to inhibit tumor cell proliferation and induce apoptosis in cancerous cells. The production of recombinant IGFBP-3 allows for high-purity preparations for in vitro and in vivo studies, facilitating insights into its biological functions and mechanisms of action. As researchers continue to delineate the pathways affected by IGFBP-3, its potential as a biotherapeutic agent is becoming increasingly apparent, opening avenues for innovative cancer treatments. Understanding the biology of IGFBP-3 not only enhances our grasp of IGF signaling but also presents opportunities for novel interventions in diseases linked to IGF dysregulation, thereby underlining the importance of ongoing research in this critical field.